オラパリブ,ペムブロリズマブ,カルボプラチンは,再発性または転移性頭頸部状細胞癌の第一線治療:第2相試験
PubMedで要約を見る
まとめ
この要約は機械生成です。この第2相試験では,オラパリブ,ペムブロリズマブ,カルボプラチンにより,再発性または転移性頭頸部状細胞癌 (HNSCC) の客観的応答率 (ORR) が有意に改善された. この組み合わせ治療は,HNSCC患者にとって有望な新しい第一線治療の選択肢です.
科学分野
- 腫瘍学
- 臨床試験
- 頭頸部がんの研究
背景
- 頭頸部状細胞癌 (HNSCC) は,しばしば同類複合DNA修復の障害を示します.
- この障害はHNSCCをポリ (ADP-リボス) ポリメラーゼ (PARP) 阻害剤とプラチナ化学療法に敏感にする.
- PARP阻害剤と抗PD-1抗体は,相乗効果のある抗腫瘍効果を示しています.
研究 の 目的
- 再発性または転移性 (RM) HNSCCの第一線治療として,ペムブロリズマブおよびカルボプラチンと併用したオラパリブ (PARP阻害剤) の有効性を評価する.
- フローロウラシル,ペンブロリズマブ,プラチナ治療の過去のデータと比較して,この組み合わせがより高い客観的な応答率 (ORR) をもたらすかどうかを判断する.
- 反応の持続時間 (DoR),無進行生存期 (PFS),全生存期 (OS) を含む二次エンドポイントの評価.
主な方法
- サイモン最適の2段階設計を用いた臨床試験
- 患者はオラパリブ,ペムブロリズマブ,カルボプラチンを最大6回のサイクルで投与し,その後オラパリブとペムブロリズマブを投与した.
- 主要エンドポイントは,RECIST v1.1 による客観的な応答を独立に評価した.
主要な成果
- 29人の評価可能な患者では,客観的な応答率 (ORR) は51. 7% (90%CI,35. 2から68. 0) であり,事前に定義された値を超えた (P=0. 04).
- 治療応答の平均期間は14. 1ヶ月でした.
- 平均進行性生存期 (PFS) は7. 8ヶ月,平均全生存期 (OS) は24. 5ヶ月でした. 常見のグレード3〜4の有害事象には,中性子減少症 (50%) と貧血 (23%) が含まれる.
結論
- オラパリブ,ペムブロリズマブ,カルボプラチンによるRM- HNSCCの第一線治療では,従来の対照群よりも高いORRが得られました.
- この併用治療は,再発性または転移性HNSCCの患者にとって潜在的に改善された治療戦略です.
- 観察された有効性は,より大きな試験でさらなる調査を正当化します.
関連する概念動画
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

